Deletion of the multidrug resistance protein MRP1 gene in acute myeloid leukemia: The impact on MRP activity

Blood

Volumn 95, Issue 11, 2000, Pages 3514-3519

  Van Der Kolk, Dorina M ^b   Vellenga, Edo ^a   Van Der Veen, Anneke Y ^b   Noordhoek, Leonore ^b   Timmer Bosscha, Hetty ^b   Ossenkoppele, Gert J ^b   Raymakers, Reinier A ^b   Müller, Michael ^b   Van Den Berg, Eva ^b   De Vries, Elisabeth G E ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; PROTEIN INHIBITOR; VERLUKAST;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW BIOPSY; CHROMOSOME 16; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FLOW CYTOMETRY; GENE DELETION; GENE THERAPY; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0034210950     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.11.3514     Document Type: Article

References (34)

1. Simon M, Schindler M. Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci U S A. 1994;91:3497.
2. Cole SPC, Bhardwaj G, Gerlach JH, et al. Overexpression of a novel transporter gene in a multidrug resistant human lung cancer cell line. Science. 1992;258:1650.
3. Müller M, Meijer C, Zaman GJ, et al. Overexpression of the gene encoding the multidrug resistance-associated protein results in increase-dATP-dependent gluthatione S-conjugate transport. Proc Natl Acad Sci U S A. 1994;91:13,033.
4. Cole SPC, Deeley RG. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioessays. 1998;20:931.
5. Grant CE, Valdimarsson G, Hiptner DR, Almquist KC, Cole SPC, Deeley RG. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res. 1994;54:357.
6. Taniguchi K, Wada M, Kohno K, et al. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res. 1996;56:4124.
7. Kool M, de Haas M, Scheffer GL, et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4 and MRP5, homologs of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 1997;57:3537.
8. Kool M, van der Linden M, de Haas M, Baas F, Borst P. Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. Cancer Res. 1999;59:175.
9. Longhurst TJ, O'Neill GM, Harvie RM, Davey RA. The anthracycline resistance-associated (ara) gene, a novel gene associated with multidrug resistance in a human leukaemia cell line. Br J Cancer. 1996;74:1331.
10. Filipits M, Suchomel RW, Zochbauer S, Brunner R, Lechner K, Pirker R. Multidrug resistance-associated protein in acute myeloid leukemia: no impact on treatment outcome. Clin Cancer Res. 1997;3:1419.
11. Legrand O, Simonin G, Parrot J-Y, Zittoun R, Marie J-P. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood. 1998;91:4480.
12. Van der Kolk DM, de Vries EGE, Koning JA, van den Berg E, Müller M, Vellenga E. Activity and expression of the multidrug resistance proteins MRP1 and MRP2 in acute myeloid leukemia cells, tumor cell lines and normal hematopoietic CD34+ peripheral blood cells. Clin Cancer Res. 1998;4:1727.
13. Lorico A, Rappa G, Finch RA, Yang D, Flavell RA, Sartorelli AC. Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione. Cancer Res. 1997;57:5238.
14. Wijnholds J, Evers R, van Leusden MR, et al. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat Med. 1997;3:1275.
15. LeBeau MM, Larson RA, Bitter MA, Vardiman JW, Golomb HM, Rowley JD. Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. N Engl J Med. 1983;309:630
16. Schiffer CA, Lee EJ, Tomiyasu T, Wiemik PH, Testa JR. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood. 1989;73:263.
17. Kuss BJ, Deeley RG, Cole SPC, et al. Deletion of gene for multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16: prognostic implications. Lancet. 1994;343:1531.
18. Liu P, Tarlé SA, Hajra A, et al. Fusion between transcription factor CBFβ/PEP2β and a myosin heavy chain in acute myeloid leukemia. Science. 1993;261:1041.
19. Kuss BJ, O'Neill GM, Eyre H, Doggett NA, Callen DF, Davey RA. ARA, a novel ABC transporter, is located at 16p13.1, is deleted in inv(16) leukemias, and is shown to be expressed in primitive hematopoietic precursors. Genomics. 1998;51: 455.
20. Leier J, Jedlitschky G, Buchholz U, Cole SPC, Deeley RG, Keppler D. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem. 1994;269:27,807.
21. Gralnick HR. Classification of acute leukemia. Ann Intern Med. 1977;87:740.
22. Zijlstra JG, de Vries EGE, Mulder NH. Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res. 1987;47:1780.
23. Zaman GJR, Flens MJ, van Leusden MR, et al. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci U S A. 1994;91:8822.
24. O'Neill GM, Peters GB, Harvie RM, MacKenzie HB, Henness S, Davey RA. Amplification and expression of the ABC transporters ARA and MRP in a series of multidrug-resistant leukaemia cell sublines. Br J Cancer. 1998;77:2076.
25. Jones TR, Zamboni R, Belley M, et al. Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol. 1989;67:17.
26. Löwenberg B, Boogaerts MA, Daenen SM, et al. Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol. 1997;15:3496.
27. Löwenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy - the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report: European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol. 1998;15:872.
28. Zittoun R. The EORTC trials for acute myelogenous leukemia: EORTC Leukemia Cooperative Group: European Organisation of Research and Treatment of Cancer. Hematol Cell Ther. 1996; 38:247.
29. Campbell L, Challis J, Fok T, Garson OM. Chromosome 16 abnormalities associated with myeloid malignancies. Genes Chromosomes Cancer. 1991;3:55.
30. Kuss BJ, Deeley RG, Cole SPC, et al. The biological significance of the multidrug resistance gene MRP in inversion 16 leukemias. Leuk Lymphoma. 1996;20:357.
31. Van der Reijden BA, Lombardo M, Dauwerse H, et al. RT-PCR diagnosis of patients with acute nonlymphocytic leukemia and inv(16)(p13q22) and identification of new alternative splicing in CBFB-MYH11 transcripts. Blood. 1995;86:277.
32. Claxton DF, Liu P, Hsu HB, et al. Detection of fusion transcripts generated by the inversion 16 chromosome in acute myelogenous leukemia. Blood. 1994;83:1750.
33. Marlton P, Claxton DF, Liu P, et al. Molecular characterization of 16p deletions associated with inversion 16 defines the critical fusion for leukemogenesis. Blood. 1995;85:772.
34. Springall FH, Lukeis RL, Tyrell V, Joshua DE, Iland HJ. Identification of a novel CBFB-MYH11 fusion transcript in a patient with AML and inversion of chromosome 16. Leukemia. 1998;12: 2034.